Literature DB >> 14719109

Deletion in p16INK4a and loss of p16 expression in human skin primary and metastatic melanoma cells.

Hong Zhang1, Inger Rosdahl.   

Abstract

p16INK4a gene mapped at chromosome 9p21 region encodes a tumor suppressor protein p16 which is frequently inactivated in human cancers, including skin melanoma. In order to clarify the importance of p16 alterations in melanoma, we examined the deletions of p16INK4a and expression of p16 protein in eight unselected primary and metastatic melanoma cell lines from human skin melanomas. Normal skin melanocytes were used as controls. Deletions of entire exons in the p16INK4a gene were detected by PCR technique and expression of the p16 protein was examined by Western blotting and immunocytochemistry. Results showed that the fragments from exons 2A, 2C and 3 in p16INK4a gene were totally deleted in the metastatic melanoma cell line, FM28.7 and the fragment from exon 3 was deleted in the metastatic melanoma cell line, FM55M2. P16 protein was strongly expressed in two of the primary melanomas cell lines (FM55P and RaH3). The p16 protein was weakly expressed in one of the metastatic melanoma cell lines (FM55M1) and negative in the other metastasis (FM55M2) as compared to their matched primary melanoma cells (FM55P). The p16 protein was strongly expressed in normal skin melanocytes. Immunocytochemistry showed that p16 protein was mainly localized in the nuclei of the melanoma cells and normal melanocytes, if it was expressed. Deletions of p16INK4a gene was uncommon and loss of p16 protein expression was common event in melanoma, especially in the later stages of melanoma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14719109

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  5 in total

1.  P16 protein expression in primary cutaneous melanoma with positive and negative lymph node biopsies: Particular aspects of a study performed at the Hospital de Clinicas de Porto Alegre, Brazil.

Authors:  Jac Fauri; F Ricardi; Es Diehl; A Cartell; R Furian; L Bakos; Mi Edelweiss
Journal:  Can J Plast Surg       Date:  2011

2.  Deletion at chromosome arm 9p in relation to BRAF/NRAS mutations and prognostic significance for primary melanoma.

Authors:  Caroline Conway; Samantha Beswick; Faye Elliott; Yu-Mei Chang; Juliette Randerson-Moor; Mark Harland; Paul Affleck; Jerry Marsden; D Scott Sanders; Andy Boon; Margaret A Knowles; D Timothy Bishop; Julia A Newton-Bishop
Journal:  Genes Chromosomes Cancer       Date:  2010-05       Impact factor: 5.006

3.  PERK Is a Haploinsufficient Tumor Suppressor: Gene Dose Determines Tumor-Suppressive Versus Tumor Promoting Properties of PERK in Melanoma.

Authors:  Dariusz Pytel; Yan Gao; Katarzyna Mackiewicz; Yuliya V Katlinskaya; Kirk A Staschke; Maria C G Paredes; Akihiro Yoshida; Shuo Qie; Gao Zhang; Olga S Chajewski; Lawrence Wu; Ireneusz Majsterek; Meenhard Herlyn; Serge Y Fuchs; J Alan Diehl
Journal:  PLoS Genet       Date:  2016-12-15       Impact factor: 5.917

Review 4.  Current understanding of epigenetics role in melanoma treatment and resistance.

Authors:  Mohsen Karami Fath; Ali Azargoonjahromi; Asma Soofi; Faezeh Almasi; Shahnaz Hosseinzadeh; Saeed Khalili; Kamran Sheikhi; Saeid Ferdousmakan; Soroor Owrangi; Minoovash Fahimi; Hamidreza Zalpoor; Mohsen Nabi Afjadi; Zahra Payandeh; Navid Pourzardosht
Journal:  Cancer Cell Int       Date:  2022-10-12       Impact factor: 6.429

5.  Promoter region hypermethylation and mRNA expression of MGMT and p16 genes in tissue and blood samples of human premalignant oral lesions and oral squamous cell carcinoma.

Authors:  Vikram Bhatia; Madhu Mati Goel; Annu Makker; Shikha Tewari; Alka Yadu; Priyanka Shilpi; Sandeep Kumar; S P Agarwal; Sudhir K Goel
Journal:  Biomed Res Int       Date:  2014-06-02       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.